FIRST-IN-HUMAN PHASE 1 STUDY OF ETC-159 AN ORAL PORCN INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMO

来源 :亚太药物研发领袖峰会(Asia Pharma R&D Leaders Summit 2018) | 被引量 : 0次 | 上传用户：yinzheng1974

【摘要】

：

OBJECTIVES Primary: Maximum Tolerated Dose (MTD) and Recommended Dose (RD).Secondary: Safety, Tolerability and Pharmacokinetics (PK).Exploratory: Pharmacodynami

【作者】

：

M.Ng D.Tan V.Subbiah W.Messersmith V.Teneggi V.Novotny Diermayr K.Ethirajulu P.Yeo D.Chen B.H.Gan L.H.Lee S.Blanchard R.Nellore M.A.Lee J.Hill B.Madan D.Virshup A.Matter

【机构】

：

NationalCancerCentre(NCC),SingaporeNationalUniversityHospital(NUH),SingaporeMDAndersonCancerCenter,H

【出处】

：

亚太药物研发领袖峰会(Asia Pharma R&D Leaders Summit 2018)

【发表日期】

：

2018年4期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

OBJECTIVES Primary: Maximum Tolerated Dose (MTD) and Recommended Dose (RD).Secondary: Safety, Tolerability and Pharmacokinetics (PK).Exploratory: Pharmacodynamic (PD) markers in hair follicles, blood and tumor (Axin2 and p-LRP6).Serum biomarkers of bone turnover (β-CTX, P1 NP);efficacy.

其他文献

Modeling and Simulation in China Our Practice

Contents 1.Brief history of pharmacometrics in China 1979-2000: PD, PK, statistical model 2000-2015: PPK, PK-PD, MBMA 2.China status of pharmacometrics only pre

会议

Combining Bottom-up and Top-down methods to assessing ethnic difference in Pharmacokinetics initial

Outline · Trends in globalization of clinical drug development and ethnicity focused regulatory environment · Mechanisms for ethnic differences in drug respon

会议

Application of Population PharmacokineticsPharmacodynamics Model in Clinical Research of Antimicrobi

Content 1.Use of PPK, PK/PD in clinical research of antimicrobial agents 2.PPK and PK/PD guide optimization of treatment regimen 3.PPK and PK/PD guide treatment

会议

Recent European-Led Developments in Quantitative Pharmacology Model Informed Drug Discovery and Deve

·Drug development decision makers need In rely on robust rationale to select drug candidates, targets, trial designs, dose regimens, patient populations and su

会议

PKPD modeling and simulation and its application in the optimization of therapeutic regimens of anti

Cancer therapy PD of Irreversible Effects: Phase-nonspecific PD of Irreversible Effects: Phase-nonspecific PD of Irreversible Effects: Cell-cycle Specific

会议

Innovation in China Through Collaborative Research Organization(CRO)

BIODURO The Spring is here! The Spring of Drug Discovery in China is here Talents Policy Money Entrepreneurship Basic research

会议

良好药典规范(Gphp)全球协调性之业界视角

致谢中国外商投资企业协会药品研制和开发行业委员会(RDPAC)的成员-默沙东中国有限公司,Wendy Yu-罗氏(中国)控股有限公司,Melly Lin

会议

Cardiovascular Safety During Oncology Drug Development

Were developing treatments for cancer Why worry about rare cardiac side effects?

会议

乌克兰国家药典现状与未来

乌克兰国家药典的地位:根据药品法乌克兰国家药典是一部法案.药典的要求对生产,贮藏,分发和使用药品的所有乌克兰企业和院校具有强制性,不管他们的所有权如何.

会议

Regenerated Human Myocardium-developing Novel Cellular Therapy for Anti-Heart Failure

Background Stem Cell Based Technologies have become a Therapeutic Strategy Cellular Replacement & Repair Biomaterials & Organ Regeneration Immunology and Micro-

会议

FIRST-IN-HUMAN PHASE 1 STUDY OF ETC-159 AN ORAL PORCN INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMO

其他学术论文